Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms - Mengshi Hu; Tao Yang; Linyu Yang; Lu Niu; Jinbing Zhu; Ailin Zhao; Mingsong Shi; Xue Yuan; Minghai Tang; Jianhong Yang; Heying Pei; Zhuang Yang; et al. (Blood Cancer Journal, 2024)